Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QL1706 + Chemotherapy +/- Bevacizumab in Advanced Pancreatic Cancer
NCT06313970Phase 2Active, not recruiting
- Sponsor
- Fudan University
- Start
- Jun 2024
- Primary completion
- Dec 2025
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of QL1706 in pancreatic cancer (PC) (2 arms), sponsored by Fudan University. Primary endpoint: Objective Response Rate at 1 year. Started Jun 2024; status: active, not recruiting.
02
Drugs
QL1706
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT06313970.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06313970.